Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on AI's impact on compliance, auditing, and employee experience in HCM - Thomson Reuters tax and accounting

AI's impact on compliance, auditing, and employee experience in HCM  Thomson Reuters tax and accounting

AI's impact on compliance, auditing, and employee experience in HCM - Thomson Reuters tax and accounting

Click here to get full coverage on Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy - nature.com

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy  nature.com

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy - nature.com

Click here to get full coverage on AI Model Better Predicts Sudden Deaths in Hypertrophic Cardiomyopathy - MedPage Today

AI Model Better Predicts Sudden Deaths in Hypertrophic Cardiomyopathy  MedPage Today

AI Model Better Predicts Sudden Deaths in Hypertrophic Cardiomyopathy - MedPage Today

Click here to get full coverage on HCM tech consultancy HR Crowd hires Ben Bach as NSW practice director - ARNnet

HCM tech consultancy HR Crowd hires Ben Bach as NSW practice director  ARNnet

HCM tech consultancy HR Crowd hires Ben Bach as NSW practice director - ARNnet

Click here to get full coverage on Patient story: Life after HCM — Willem’s journey to an active new normal - Bristol Myers Squibb

Patient story: Life after HCM — Willem’s journey to an active new normal  Bristol Myers Squibb

Patient story: Life after HCM — Willem’s journey to an active new normal - Bristol Myers Squibb

Click here to get full coverage on Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy - University of Utah Health

Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy  University of Utah Health

Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy - University of Utah Health

Click here to get full coverage on Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM  TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Click here to get full coverage on Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM - ScienceDirect.com

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM  ScienceDirect.com

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM - ScienceDirect.com

Click here to get full coverage on Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM - HCPLive

Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM  HCPLive

Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM - HCPLive

Click here to get full coverage on Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM | Circulation - American Heart Association Journals

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM | Circulation  American Heart Association Journals

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM | Circulation - American Heart Association Journals

Click here to get full coverage on Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics - JACC Journals

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics  JACC Journals

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics - JACC Journals

Click here to get full coverage on Doctor-Approved Tips for Caring for Yourself With HCM - HealthCentral

Doctor-Approved Tips for Caring for Yourself With HCM  HealthCentral

Doctor-Approved Tips for Caring for Yourself With HCM - HealthCentral

Click here to get full coverage on 400 international exhibitors attend precision engineering and manufacturing exhibition in HCM City - vietnamnews.vn

400 international exhibitors attend precision engineering and manufacturing exhibition in HCM City  vietnamnews.vn

400 international exhibitors attend precision engineering and manufacturing exhibition in HCM City - vietnamnews.vn

Click here to get full coverage on Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025  Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Click here to get full coverage on Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology - American Animal Hospital Association - AAHA

Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology  American Animal Hospital Association - AAHA

Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology - American Animal Hospital Association - AAHA

Click here to get full coverage on BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial  FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

Click here to get full coverage on Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings - nature.com

Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings  nature.com

Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings - nature.com

Click here to get full coverage on Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM  ScienceDirect.com

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com

Click here to get full coverage on Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial - American Heart Association Journals

Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial  American Heart Association Journals

Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial - American Heart Association Journals

Click here to get full coverage on Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis - ScienceDirect.com

Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis  ScienceDirect.com

Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis - ScienceDirect.com

Click here to get full coverage on First drug shown to reverse feline HCM expected to receive FDA conditional approval - DVM360

First drug shown to reverse feline HCM expected to receive FDA conditional approval  DVM360

First drug shown to reverse feline HCM expected to receive FDA conditional approval - DVM360

Click here to get full coverage on Oracle AI Agents Help HR Leaders Reshape the Employee Experience - Oracle

Oracle AI Agents Help HR Leaders Reshape the Employee Experience  Oracle

Oracle AI Agents Help HR Leaders Reshape the Employee Experience - Oracle

Click here to get full coverage on Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy - ScienceDirect.com

Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy  ScienceDirect.com

Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy - ScienceDirect.com

Click here to get full coverage on Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy - nature.com

Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy  nature.com

Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy - nature.com

Click here to get full coverage on Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel - ScienceDirect.com

Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel  ScienceDirect.com

Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel - ScienceDirect.com

Click here to get full coverage on Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics - ScienceDirect.com

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics  ScienceDirect.com

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics - ScienceDirect.com

Click here to get full coverage on Fast Five Quiz: Obstructive HCM Management - Medscape Reference

Fast Five Quiz: Obstructive HCM Management  Medscape Reference

Fast Five Quiz: Obstructive HCM Management - Medscape Reference

Click here to get full coverage on Intelligent HCM Software - Paycor

Intelligent HCM Software - Paycor

Click here to get full coverage on New Treatment Option For Severe HCM in Children Shows Promise - American College of Cardiology

New Treatment Option For Severe HCM in Children Shows Promise  American College of Cardiology

New Treatment Option For Severe HCM in Children Shows Promise - American College of Cardiology

Click here to get full coverage on Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)  PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Click here to get full coverage on Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial - American Heart Association Journals

Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial  American Heart Association Journals

Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial - American Heart Association Journals

Click here to get full coverage on Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results  FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Click here to get full coverage on E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM - Oracle

E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM  Oracle

E.ON Moves Global HR Operations to Oracle Fusion Cloud HCM - Oracle

Click here to get full coverage on Cytokinetics Announces Launch of EARTH-HCM, a Public Health - GlobeNewswire

Cytokinetics Announces Launch of EARTH-HCM, a Public Health  GlobeNewswire

Cytokinetics Announces Launch of EARTH-HCM, a Public Health - GlobeNewswire

Click here to get full coverage on Get up to date about HCM Image 51 - Oracle Blogs

Get up to date about HCM Image 51  Oracle Blogs

Get up to date about HCM Image 51 - Oracle Blogs

Click here to get full coverage on Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM) - American Heart Association Journals

Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM)  American Heart Association Journals

Abstract 4143175: Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM) - American Heart Association Journals

Click here to get full coverage on ADP Named Market Leader for HCM Suites 2025 by ISG Research - ADP

ADP Named Market Leader for HCM Suites 2025 by ISG Research  ADP

ADP Named Market Leader for HCM Suites 2025 by ISG Research - ADP

Click here to get full coverage on HCM City organises discussion panel on how to combat fake goods - vietnamnews.vn

HCM City organises discussion panel on how to combat fake goods  vietnamnews.vn

HCM City organises discussion panel on how to combat fake goods - vietnamnews.vn

Click here to get full coverage on Human Capital Management - CBIZ

Human Capital Management - CBIZ

Click here to get full coverage on Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - HealthCentral

Can a Blood Test Diagnose Hypertrophic Cardiomyopathy?  HealthCentral

Can a Blood Test Diagnose Hypertrophic Cardiomyopathy? - HealthCentral

Click here to get full coverage on Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry - American Heart Association Journals

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry  American Heart Association Journals

Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry - American Heart Association Journals

Click here to get full coverage on What Causes Hypertrophic Cardiomyopathy? - Verywell Health

What Causes Hypertrophic Cardiomyopathy?  Verywell Health

What Causes Hypertrophic Cardiomyopathy? - Verywell Health

Click here to get full coverage on How Hypertrophic Cardiomyopathy Is Diagnosed - Time Magazine

How Hypertrophic Cardiomyopathy Is Diagnosed  Time Magazine

How Hypertrophic Cardiomyopathy Is Diagnosed - Time Magazine

Click here to get full coverage on Hypertrophic Cardiomyopathy: State of the Art - Mayo Clinic Proceedings

Hypertrophic Cardiomyopathy: State of the Art  Mayo Clinic Proceedings

Hypertrophic Cardiomyopathy: State of the Art - Mayo Clinic Proceedings

Click here to get full coverage on Discover the Power of PeopleSoft HCM Image 52 - Oracle Blogs

Discover the Power of PeopleSoft HCM Image 52  Oracle Blogs

Discover the Power of PeopleSoft HCM Image 52 - Oracle Blogs

Click here to get full coverage on Hypertrophic Cardiomyopathy Awareness Day Is February 26 - Healthline

Hypertrophic Cardiomyopathy Awareness Day Is February 26  Healthline

Hypertrophic Cardiomyopathy Awareness Day Is February 26 - Healthline

Click here to get full coverage on New drug for obstructive HCM outperforms the current standard of care - Cardiovascular Business

New drug for obstructive HCM outperforms the current standard of care  Cardiovascular Business

New drug for obstructive HCM outperforms the current standard of care - Cardiovascular Business

Click here to get full coverage on Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year - Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year  Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Ninth Consecutive Year - Oracle

Click here to get full coverage on University of Windsor refines collaboration with Oracle Fusion Cloud ERP and HCM - Oracle

University of Windsor refines collaboration with Oracle Fusion Cloud ERP and HCM  Oracle

University of Windsor refines collaboration with Oracle Fusion Cloud ERP and HCM - Oracle

Click here to get full coverage on Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial - American Heart Association Journals

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial  American Heart Association Journals

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial - American Heart Association Journals

Click here to get full coverage on AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy - Cleveland Clinic

AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy  Cleveland Clinic

AI-Enhanced ECG Analysis Shows Strong Accuracy in Detecting Hypertrophic Cardiomyopathy - Cleveland Clinic

Click here to get full coverage on Mavacamten Still Effective for Hypertrophic Cardiomyopathy - Cleveland Clinic

Mavacamten Still Effective for Hypertrophic Cardiomyopathy  Cleveland Clinic

Mavacamten Still Effective for Hypertrophic Cardiomyopathy - Cleveland Clinic

Click here to get full coverage on Peoplesoft HCM to be unavailable early Sunday - The Daily | Case Western Reserve University

Peoplesoft HCM to be unavailable early Sunday  The Daily | Case Western Reserve University

Peoplesoft HCM to be unavailable early Sunday - The Daily | Case Western Reserve University

Click here to get full coverage on Northwell Health taps Oracle Cloud HCM and AI capabilities to support employees - Oracle

Northwell Health taps Oracle Cloud HCM and AI capabilities to support employees  Oracle

Northwell Health taps Oracle Cloud HCM and AI capabilities to support employees - Oracle

Click here to get full coverage on What to Expect From a Heart Transplant for Hypertrophic Cardiomyopathy - HealthCentral

What to Expect From a Heart Transplant for Hypertrophic Cardiomyopathy  HealthCentral

HUTCHMED DRC (HCM)

Price Chart

Key Statistics

Technicals

About HCM

Latest News

AI's impact on compliance, auditing, and employee experience in HCM - Thomson Reuters tax and accounting

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy - nature.com

AI Model Better Predicts Sudden Deaths in Hypertrophic Cardiomyopathy - MedPage Today

Advanced Charts

Top Gainers

Top Losers